- Report
- October 2024
- 189 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- March 2025
- 189 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- May 2024
- 134 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- June 2024
- 200 Pages
Global
From €7547EUR$7,950USD£6,366GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1899EUR$2,000USD£1,602GBP
- Report
- December 2024
- 201 Pages
Global
From €2373EUR$2,500USD£2,002GBP
- Report
- February 2025
- 181 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- December 2023
- 109 Pages
Global
From €2373EUR$2,500USD£2,002GBP
- Report
- April 2020
- 269 Pages
Global
From €4035EUR$4,250USD£3,403GBP
- Report
- August 2022
- 120 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- January 2022
- 60 Pages
Global
From €3750EUR$3,950USD£3,163GBP
- Report
- August 2024
- 90 Pages
Global
From €3500EUR$3,949USD£3,056GBP
The Premature Ejaculation Drug market is a subset of the Sexual and Reproductive Health Drugs market. It is composed of drugs used to treat premature ejaculation, a condition in which a man ejaculates too quickly during sexual intercourse. These drugs are typically taken orally and work by increasing the time it takes for a man to ejaculate. Common side effects of these drugs include dizziness, headache, and nausea.
The Premature Ejaculation Drug market is growing due to increased awareness of the condition and the availability of treatments. This has led to an increase in demand for these drugs, as well as an increase in research and development of new drugs.
Some companies in the Premature Ejaculation Drug market include Pfizer, Eli Lilly, and Johnson & Johnson. These companies are involved in the research, development, and marketing of drugs to treat premature ejaculation. Show Less Read more
